MedTrace Logo

Stereotactic Radiotherapy Management of Brain Metastases: the Value of a Longitudinal Multimodal Approach (POSTPONE)

NCT06029140 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2024-08-09

No results posted yet for this study

Summary

The management of brain metastases has evolved́ rapidly in recent years. It is estimated that 20% to 40% of cancer patients will develop brain metastases (BM) during the course of their disease. Whole-brain radiotherapy has long been the first-line treatment for brain metastases. However, large-scale international clinical trials conducted over the past decade have established stereotactic radiotherapy (SR) as the treatment of choice for the management of brain metastases (BM). However, even though the method of radiation delivery has evolved considerably, the problem of monitoring and managing brain metastases remains unresolved.

This study therefore has several focuses:

1. Evaluation of the benefit of early remnographic assessment (6 weeks): impact on recurrence-free survival and overall survival.
2. Evaluation of a diagnostic approach to radionecrosis: complementarity of DOPA PET and multimodal MRI.
3. The benefits of longitudinal remnographic monitoring with the development of segmentation and automated follow-up tools

Conditions

  • Brain Metastases, Adult

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Principal Investigators

  • Vincent Bourbonne, MD, PhD · Radiation Oncology Department, Brest University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-07-01
Completion
2024-09-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06029140 on ClinicalTrials.gov